BR0300314A - Agentes antidiabéticos - Google Patents

Agentes antidiabéticos

Info

Publication number
BR0300314A
BR0300314A BR0300314-0A BR0300314A BR0300314A BR 0300314 A BR0300314 A BR 0300314A BR 0300314 A BR0300314 A BR 0300314A BR 0300314 A BR0300314 A BR 0300314A
Authority
BR
Brazil
Prior art keywords
antidiabetic agents
diabetic
hyperinsulinemia
cataracts
hypercholesterolemia
Prior art date
Application number
BR0300314-0A
Other languages
English (en)
Inventor
Ronald Bruce Gammill
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0300314A publication Critical patent/BR0300314A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"AGENTES ANTIDIABéTICOS". Composto de fórmula em que n, m, Z, R^ 1^, R^ 5^, R^ 8^, R^ 9^, R^ 10^ e R^ 11^ são tal como definidos anteriormente, útil no tratamento de diabetes, resistência à insulina, neuropatia diabética, nefropatia diabética, retinopatia diabética, cataratas, hiperglicemia, hipercolesterolemia, hipertensão, hiperinsulinemia, hiperlipidemia, aterosclerose, e isquemia de tecidos, em particular isquemia do miocárdio.
BR0300314-0A 2002-02-28 2003-02-26 Agentes antidiabéticos BR0300314A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36091302P 2002-02-28 2002-02-28

Publications (1)

Publication Number Publication Date
BR0300314A true BR0300314A (pt) 2004-09-08

Family

ID=27734776

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0300314-0A BR0300314A (pt) 2002-02-28 2003-02-26 Agentes antidiabéticos

Country Status (8)

Country Link
US (2) US6821977B2 (pt)
EP (1) EP1340500A1 (pt)
JP (1) JP2004002311A (pt)
AU (1) AU2003206028A1 (pt)
BR (1) BR0300314A (pt)
CA (1) CA2419685A1 (pt)
MX (1) MXPA03000966A (pt)
WO (1) WO2003072570A1 (pt)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2445944A1 (en) * 2001-05-04 2002-11-14 Pfizer Products Inc. Method of preventing type 2 diabetes with aerosolized insulin
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
CA2503727A1 (en) * 2002-11-07 2004-05-21 Pfizer Products Inc. Anti-diabetic agents
CA2515368A1 (en) 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
WO2005007628A1 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
WO2006055462A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
US7759339B2 (en) * 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
EP1884513A4 (en) * 2005-05-23 2010-04-28 Japan Tobacco Inc PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME
US20080076742A1 (en) * 2005-10-31 2008-03-27 Wisconsin Alumni Research Foundation Methods and compositions for treating diseases associated with neovascualrization
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2096111A1 (en) * 2006-11-20 2009-09-02 Japan Tobacco Inc. Pyrazoles and use thereof as drugs
EP2285774B1 (en) 2008-06-05 2015-02-25 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Novel modulators of protein kinase signaling
US10155168B2 (en) 2012-05-08 2018-12-18 Snap Inc. System and method for adaptable avatars
US9770454B2 (en) 2013-07-14 2017-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
CA2975673A1 (en) 2015-02-05 2016-08-11 Tyrnovo Ltd. Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
US10339365B2 (en) 2016-03-31 2019-07-02 Snap Inc. Automated avatar generation
EP3535242B1 (en) 2016-10-20 2024-01-24 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Dna primase and gyrase inhibitors
US10593116B2 (en) 2016-10-24 2020-03-17 Snap Inc. Augmented reality object manipulation
US10432559B2 (en) 2016-10-24 2019-10-01 Snap Inc. Generating and displaying customized avatars in electronic messages
US10242503B2 (en) 2017-01-09 2019-03-26 Snap Inc. Surface aware lens
US10242477B1 (en) 2017-01-16 2019-03-26 Snap Inc. Coded vision system
WO2018201102A1 (en) 2017-04-27 2018-11-01 Snap Inc. Friend location sharing mechanism for social media platforms
US11122094B2 (en) 2017-07-28 2021-09-14 Snap Inc. Software application manager for messaging applications
US10586368B2 (en) 2017-10-26 2020-03-10 Snap Inc. Joint audio-video facial animation system
US11460974B1 (en) 2017-11-28 2022-10-04 Snap Inc. Content discovery refresh
US10979752B1 (en) 2018-02-28 2021-04-13 Snap Inc. Generating media content items based on location information
US10726603B1 (en) 2018-02-28 2020-07-28 Snap Inc. Animated expressive icon
US11310176B2 (en) 2018-04-13 2022-04-19 Snap Inc. Content suggestion system
US11030813B2 (en) 2018-08-30 2021-06-08 Snap Inc. Video clip object tracking
US10895964B1 (en) 2018-09-25 2021-01-19 Snap Inc. Interface to display shared user groups
US11245658B2 (en) 2018-09-28 2022-02-08 Snap Inc. System and method of generating private notifications between users in a communication session
US10904181B2 (en) 2018-09-28 2021-01-26 Snap Inc. Generating customized graphics having reactions to electronic message content
US10698583B2 (en) 2018-09-28 2020-06-30 Snap Inc. Collaborative achievement interface
US11189070B2 (en) 2018-09-28 2021-11-30 Snap Inc. System and method of generating targeted user lists using customizable avatar characteristics
US10872451B2 (en) 2018-10-31 2020-12-22 Snap Inc. 3D avatar rendering
US11176737B2 (en) 2018-11-27 2021-11-16 Snap Inc. Textured mesh building
US10861170B1 (en) 2018-11-30 2020-12-08 Snap Inc. Efficient human pose tracking in videos
US11199957B1 (en) 2018-11-30 2021-12-14 Snap Inc. Generating customized avatars based on location information
US11516173B1 (en) 2018-12-26 2022-11-29 Snap Inc. Message composition interface
US11294936B1 (en) 2019-01-30 2022-04-05 Snap Inc. Adaptive spatial density based clustering
US10936066B1 (en) 2019-02-13 2021-03-02 Snap Inc. Sleep detection in a location sharing system
US10852918B1 (en) 2019-03-08 2020-12-01 Snap Inc. Contextual information in chat
US11676199B2 (en) 2019-06-28 2023-06-13 Snap Inc. Generating customizable avatar outfits
US11188190B2 (en) 2019-06-28 2021-11-30 Snap Inc. Generating animation overlays in a communication session
US11307747B2 (en) 2019-07-11 2022-04-19 Snap Inc. Edge gesture interface with smart interactions
US11455081B2 (en) 2019-08-05 2022-09-27 Snap Inc. Message thread prioritization interface
US11320969B2 (en) 2019-09-16 2022-05-03 Snap Inc. Messaging system with battery level sharing
US11080917B2 (en) 2019-09-30 2021-08-03 Snap Inc. Dynamic parameterized user avatar stories
US11218838B2 (en) 2019-10-31 2022-01-04 Snap Inc. Focused map-based context information surfacing
US11063891B2 (en) 2019-12-03 2021-07-13 Snap Inc. Personalized avatar notification
US11128586B2 (en) 2019-12-09 2021-09-21 Snap Inc. Context sensitive avatar captions
US11263817B1 (en) 2019-12-19 2022-03-01 Snap Inc. 3D captions with face tracking
US11227442B1 (en) 2019-12-19 2022-01-18 Snap Inc. 3D captions with semantic graphical elements
US11169658B2 (en) 2019-12-31 2021-11-09 Snap Inc. Combined map icon with action indicator
US11356720B2 (en) 2020-01-30 2022-06-07 Snap Inc. Video generation system to render frames on demand
US11036781B1 (en) 2020-01-30 2021-06-15 Snap Inc. Video generation system to render frames on demand using a fleet of servers
US11217020B2 (en) 2020-03-16 2022-01-04 Snap Inc. 3D cutout image modification
US11625873B2 (en) 2020-03-30 2023-04-11 Snap Inc. Personalized media overlay recommendation
US11818286B2 (en) 2020-03-30 2023-11-14 Snap Inc. Avatar recommendation and reply
US11580682B1 (en) 2020-06-30 2023-02-14 Snap Inc. Messaging system with augmented reality makeup
US11360733B2 (en) 2020-09-10 2022-06-14 Snap Inc. Colocated shared augmented reality without shared backend
US11452939B2 (en) 2020-09-21 2022-09-27 Snap Inc. Graphical marker generation system for synchronizing users
US11615592B2 (en) 2020-10-27 2023-03-28 Snap Inc. Side-by-side character animation from realtime 3D body motion capture
US11544885B2 (en) 2021-03-19 2023-01-03 Snap Inc. Augmented reality experience based on physical items
US11636654B2 (en) 2021-05-19 2023-04-25 Snap Inc. AR-based connected portal shopping
US11673054B2 (en) 2021-09-07 2023-06-13 Snap Inc. Controlling AR games on fashion items
US11663792B2 (en) 2021-09-08 2023-05-30 Snap Inc. Body fitted accessory with physics simulation
US11734866B2 (en) 2021-09-13 2023-08-22 Snap Inc. Controlling interactive fashion based on voice
US11636662B2 (en) 2021-09-30 2023-04-25 Snap Inc. Body normal network light and rendering control
US11651572B2 (en) 2021-10-11 2023-05-16 Snap Inc. Light and rendering of garments
US11790614B2 (en) 2021-10-11 2023-10-17 Snap Inc. Inferring intent from pose and speech input
US11823346B2 (en) 2022-01-17 2023-11-21 Snap Inc. AR body part tracking system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0670831A1 (en) * 1993-09-28 1995-09-13 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
JP2003506358A (ja) * 1999-07-29 2003-02-18 エギシュ ヂョヂセルヂャール エルテー イソキノリン誘導体、該誘導体を含有する医薬組成物及び活性物質の製法
AU7315700A (en) * 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
DE10115994A1 (de) * 2001-03-30 2002-10-10 Wella Ag (p-Amino-hydroxyphenyl)acrylamid-Derivate und diese Verbindungen enthaltende Färbemittel
CA2448894A1 (en) * 2001-05-31 2002-12-05 Bristol-Myers Squibb Company Cinnamide derivatives as kcnq potassium channel modulators
DE20110355U1 (de) * 2001-06-22 2001-08-30 Wella Ag, 64295 Darmstadt (Dihydroxyphenyl)-acrylamid-Derivate und diese Verbindungen enthaltende Färbemittel

Also Published As

Publication number Publication date
AU2003206028A1 (en) 2003-09-09
JP2004002311A (ja) 2004-01-08
US20050020661A1 (en) 2005-01-27
EP1340500A1 (en) 2003-09-03
US20030199553A1 (en) 2003-10-23
WO2003072570A1 (en) 2003-09-04
US6821977B2 (en) 2004-11-23
CA2419685A1 (en) 2003-08-28
MXPA03000966A (es) 2003-09-04

Similar Documents

Publication Publication Date Title
BR0300314A (pt) Agentes antidiabéticos
MXPA05011702A (es) Agentes antidiabeticos.
BR0316099A (pt) Agentes antidiabéticos
PT1088824E (pt) Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
ATE476425T1 (de) Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
DK1349843T3 (da) Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer
ATE485049T1 (de) Physiologisch aktive zusammensetzung gegen diabetes
BR0317451A (pt) Composto, composição farmacêutica, e, uso de um composto
NO20044534L (no) Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer
ECSP045482A (es) Inhibidores de la 11-beta-hydroxiesteroide deshidrogenasa 1 para el tratamiento de la diabetes, obesidad y dislipidemia
ECSP055813A (es) Quinolin-, isoquinolin- y quinazolin-oxialquilamidas y su uso como fungicidas
BR122012009534B8 (pt) 4-[2-(4-metil-fenil-sulfanil)-fenil]-piperidina, seu uso e composição farmacêutica compreendendo o referido composto
JP2009501177A5 (pt)
JP2009501178A5 (pt)
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
ATE424821T1 (de) Pyrrolopyridin-2-karbonsäureamide
BRPI0512310A (pt) compostos quìmicos
BRPI0409465A (pt) derivados de carboxamida como agentes antidiabéticos
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
DE60330890D1 (de) Hiv-integrase-hemmers, pharmazeutischen zusammensetzung und ihre anwendung
BR9909739A (pt) Benzotiadiazóis e derivados
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
BR0317678A (pt) Piridodiazinas como fungicidas de planta
BRPI0607085A2 (pt) derivados de oximas heterocìclicos, o respectivo processo de preparação e a respectiva utilização como agentes hipoglicemiantes e hipolipemiantes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A , 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2038 DE 26/01/2010.